NSPR - InspireMD Inc Stock Price, Fair Value and News

1.95USD+0.01 (+0.52%)Delayed as of 01 May 2024, 09:56 am ET

Market Summary

USD1.95+0.01

Delayedas of 01 May 2024, 09:56 am

0.52%

NSPR Stock Price

View Fullscreen

NSPR RSI Chart

NSPR Valuation

Market Cap

45.5M

Price/Earnings (Trailing)

-2.28

Price/Sales (Trailing)

7.33

EV/EBITDA

-1.83

Price/Free Cashflow

-2.72

NSPR Price/Sales (Trailing)

NSPR Profitability

Operating Margin

60.84%

EBT Margin

-319.92%

Return on Equity

-50.42%

Return on Assets

-41.8%

Free Cashflow Yield

-36.82%

NSPR Fundamentals

NSPR Revenue

Revenue (TTM)

6.2M

Rev. Growth (Yr)

71.64%

Rev. Growth (Qtr)

13.17%

NSPR Earnings

Earnings (TTM)

-19.9M

Earnings Growth (Yr)

-11.56%

Earnings Growth (Qtr)

-4.38%

Breaking Down NSPR Revenue

52 Week Range

1.293.77

(Low)(High)

Last 7 days

-2.5%

Last 30 days

-18.6%

Last 90 days

-31.8%

Trailing 12 Months

28.7%

How does NSPR drawdown profile look like?

NSPR Financial Health

Current Ratio

7.34

Debt/Equity

0.03

Debt/Cashflow

-14.9

NSPR Investor Care

Shares Dilution (1Y)

158.53%

Diluted EPS (TTM)

-1.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	5.2M	5.3M	5.5M	6.2M
2022	4.7M	5.2M	5.5M	5.2M
2021	2.5M	3.2M	3.3M	4.5M
2020	4.3M	3.3M	3.3M	2.5M
2019	3.0M	3.4M	3.5M	3.7M
2018	3.2M	3.6M	3.6M	3.6M
2017	1.9M	2.0M	2.2M	2.8M
2016	2.4M	2.3M	2.1M	1.9M
2015	1.8M	2.3M	2.7M	2.3M
2014	6.1M	4.8M	3.5M	2.8M
2013	4.3M	4.9M	5.9M	6.1M
2012	5.5M	5.3M	3.9M	3.9M
2011	4.5M	4.7M	5.4M	6.0M
2010	0	3.9M	4.4M	4.9M
2009	0	0	0	3.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of InspireMD Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 23, 2024	shore craig	acquired	-	-	238,625	cfo and cao
Jan 23, 2024	berman michael	acquired	-	-	29,032	-
Jan 23, 2024	kester thomas j	acquired	-	-	29,032	-
Jan 23, 2024	slosman marvin	acquired	-	-	563,499	ceo and president
Jan 23, 2024	verta patrick	acquired	-	-	85,720	evp clinical/medical affairs
Jan 23, 2024	roubin gary s	acquired	-	-	29,032	-
Jan 23, 2024	gleason shane thomas	acquired	-	-	238,625	chief commercial officer
Jan 23, 2024	tommasoli andrea	acquired	-	-	238,625	chief operating officer
Jan 23, 2024	stuka paul	acquired	-	-	43,548	-
Jan 23, 2024	arnold kathryn	acquired	-	-	29,032	-

Which funds bought or sold NSPR recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 26, 2024	BELLEVUE ASSET MANAGEMENT, LLC	unchanged	-	216	4,081	-%
Apr 26, 2024	McKinley Carter Wealth Services, Inc.	unchanged	-	-4,399	23,701	-%
Apr 25, 2024	Rosalind Advisors, Inc.	reduced	-25.85	-973,760	1,626,040	1.52%
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	-	-	-%
Apr 25, 2024	Mesirow Financial Investment Management, Inc.	unchanged	-	-13,197	71,103	-%
Apr 23, 2024	Global Retirement Partners, LLC	unchanged	-	-19.00	64.00	-%
Apr 19, 2024	Financial Perspectives, Inc	sold off	-100	-3,094	-	-%
Apr 12, 2024	AdvisorNet Financial, Inc	unchanged	-	-3,863	20,817	-%
Feb 15, 2024	Nantahala Capital Management, LLC	added	133	5,831,960	11,613,500	0.35%
Feb 14, 2024	ORBIMED ADVISORS LLC	added	14.67	-88,656	5,994,870	0.12%

Are Funds Buying or Selling NSPR?

Are funds buying NSPR calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NSPR

No. of Funds

Unveiling InspireMD Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 25, 2024	rosalind advisors, inc.	9.9%	686,062	SC 13G/A
Feb 14, 2024	nantahala capital management, llc	9.9%	2,162,392	SC 13G
Feb 14, 2024	rosalind advisors, inc.	9.9%	989,940	SC 13G/A
Feb 14, 2024	orbimed advisors llc	9.9%	2,133,405	SC 13G
Jun 16, 2023	shore craig	8.01%	1,700,159	SC 13D
Jun 08, 2023	rosalind advisors, inc.	9.9%	1,860,405	SC 13G
May 24, 2023	soleus private equity fund iii, l.p.	9.9%	2,199,118	SC 13G
May 22, 2023	marshall wace north america l.p.	9.9%	1,860,405	SC 13G
Feb 11, 2022	lind global macro fund lp	2.1%	177,333	SC 13G/A
Feb 09, 2021	lind global macro fund lp	5.3%	2,055,163	SC 13G/A

Recent SEC filings of InspireMD Inc

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	SC 13G/A	Major Ownership Report
Apr 18, 2024	ARS	ARS
Apr 18, 2024	DEF 14A	DEF 14A
Apr 18, 2024	DEFA14A	DEFA14A
Apr 02, 2024	8-K	Current Report
Mar 26, 2024	8-K	Current Report
Mar 06, 2024	8-K	Current Report
Mar 05, 2024	10-K	Annual Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G	Major Ownership Report

Peers (Alternatives to InspireMD Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	183.9B	40.1B	-6.77%	-4.63%	32.13	4.58	-8.12%	-17.45%
BDX	67.8B	19.5B	-5.19%	-11.58%	53.96	3.48	4.02%	-22.04%
ALGN	21.2B	3.9B	-13.89%	-11.01%	47.65	5.49	3.42%	23.09%
BAX	20.5B	14.8B	-5.55%	-14.80%	7.72	1.38	2.12%	209.17%
MID-CAP
ATR	9.6B	3.5B	0.34%	19.07%	30.58	2.7	6.16%	35.06%
HSIC	8.9B	12.3B	-8.26%	-15.92%	21.4	0.72	-2.44%	-22.68%
BIO	7.9B	2.7B	-22.01%	-40.57%	-12.36	2.95	-4.68%	82.43%
XRAY	6.2B	4.0B	-9.58%	-29.21%	-46.27	1.57	1.10%	85.84%
AXNX	3.4B	387.1M	-3.48%	13.50%	-213.32	8.77	30.82%	65.60%
PDCO	2.3B	6.6B	-7.88%	-6.70%	11.79	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-14.42%	-16.17%	-1.93	0.41	7.73%	-1066.14%
ANIK	383.9M	166.7M	1.93%	-0.42%	-4.64	2.3	6.67%	-456.34%
ANGO	231.9M	324.0M	-1.36%	-32.67%	-1.21	0.72	-3.19%	-337.41%
APYX	49.5M	52.3M	5.15%	-61.35%	-2.65	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-17.86%	283.33%	-0.3	0.96	5.77%	8.23%

InspireMD Inc News

Latest updates

InspireMD Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	13.2%	1,761,000	1,556,000	1,649,000	1,239,000	1,026,000	1,431,000	1,531,000	1,183,000	1,380,000	1,071,000	1,038,000	1,006,000	158,000	980,000	313,000	1,034,000	1,013,000	939,000	1,354,000	415,000	822,000
Gross Profit	15.3%	505,000	438,000	491,000	373,000	198,000	366,000	431,000	122,000	294,000	92,000	262,000	106,000	-390,000	298,000	-120,000	295,000	259,000	128,000	442,000	-73,000	227,000
Operating Expenses	3.9%	6,313,000	6,077,000	5,806,000	4,754,000	5,134,000	4,976,000	5,112,000	4,608,000	4,225,000	4,123,000	3,702,000	3,420,000	3,328,000	2,493,000	2,326,000	2,316,000	2,765,000	2,125,000	2,625,000	3,057,000	2,433,000
S&GA Expenses	49.4%	1,309,000	876,000	892,000	788,000	1,087,000	845,000	986,000	746,000	761,000	802,000	636,000	708,000	617,000	485,000	377,000	624,000	605,000	537,000	620,000	634,000	564,000
R&D Expenses	-3.6%	2,035,000	2,110,000	1,993,000	1,843,000	2,013,000	2,061,000	2,056,000	1,680,000	1,534,000	1,495,000	1,290,000	839,000	720,000	546,000	444,000	523,000	522,000	442,000	865,000	1,125,000	637,000
EBITDA Margin	2.0%	-3.16	-3.23	-3.30	-3.38	-3.42	-3.07	-3.19	-3.29	-3.14	-3.00	-3.08	-3.99	-3.95	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-4,817,000	-4,529,000	-4,636,000	-4,481,000	-4,052,000	-4,071,000	-3,507,000	-3,243,000	-	-	-2,480,000	-	-2,533,000	-2,070,000	-2,206,000	-3,207,000	-2,213,000
EBT Margin	5.2%	-3.20	-3.38	-3.45	-3.53	-3.57	-3.20	-3.34	-3.45	-3.31	-3.22	-3.31	-4.29	-4.24	-	-	-	-	-	-	-	-
Net Income	-4.4%	-5,405,000	-5,178,000	-5,077,000	-4,256,000	-4,845,000	-4,529,000	-4,636,000	-4,481,000	-4,097,000	-4,071,000	-3,507,000	-3,243,000	-3,853,000	-2,233,000	-2,480,000	-1,978,000	-2,557,000	-2,070,000	-2,206,000	-3,207,000	-2,213,000
Net Income Margin	9.3%	-3.21	-3.54	-3.50	-3.49	-3.58	-3.21	-3.35	-3.46	-3.32	-4.48	-4.03	-4.81	-4.24	-	-	-	-	-	-	-	-
Free Cashflow	-6.1%	-4,392,000	-4,139,000	-3,370,000	-4,856,000	-3,290,000	-5,330,000	-3,224,000	-4,171,000	-3,008,000	-4,297,000	-2,582,000	-3,667,000	-2,262,000	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-4.8%	48.00	50.00	54.00	20.00	25.00	28.00	33.00	35.00	40.00	43.00	46.00	49.00	18.00	16.00	18.00	7.00	10.00	12.00	9.00	10.00	12.00
Current Assets	-5.5%	44.00	47.00	51.00	17.00	21.00	25.00	30.00	33.00	37.00	40.00	44.00	46.00	15.00	13.00	16.00	5.00	8.00	10.00	7.00	8.00	11.00
Cash Equivalents	-30.3%	10.00	14.00	12.00	4.00	5.00	4.00	6.00	8.00	12.00	13.00	41.00	44.00	13.00	11.00	14.00	3.00	6.00	7.00	5.00	6.00	9.00
Inventory	14.1%	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	1.00
Net PPE	16.9%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	0.00	0.00
Liabilities	20.4%	8.00	7.00	7.00	6.00	7.00	6.00	7.00	5.00	6.00	6.00	6.00	5.00	6.00	4.00	5.00	4.00	4.00	4.00	4.00	4.00	4.00
Current Liabilities	28.4%	6.00	5.00	5.00	4.00	5.00	4.00	5.00	4.00	4.00	4.00	4.00	3.00	4.00	3.00	3.00	3.00	3.00	2.00	2.00	3.00	3.00
Shareholder's Equity	-8.7%	40.00	43.00	47.00	13.00	17.00	22.00	26.00	30.00	34.00	37.00	41.00	44.00	12.00	11.00	13.00	3.00	5.00	8.00	6.00	6.00	9.00
Retained Earnings	-2.5%	-221	-216	-210	-205	-201	-196	-192	-187	-183	-179	-174	-171	-168	-164	-162	-159	-157	-155	-153	-150	-147
Additional Paid-In Capital	0.6%	261	259	258	219	219	219	218	217	217	216	216	215	180	176	175	163	163	163	159	156	156
Shares Outstanding	2.1%	22.00	21.00	21.00	8.00	8.00	8.00	8.00	8.00	8.00	7.00	8.00	6.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	46.00	-	-	-	16.00	-	-	-	39.00	-	-	-	16.00	-	-	-	5.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-3.3%	-4,177	-4,043	-3,325	-4,831	-3,195	-5,104	-3,109	-4,134	-2,901	-4,140	-2,528	-3,641	-2,200	-3,044	-1,483	-2,354	-1,568	-1,860	-2,897	-3,485	-1,803
Share Based Compensation	1.7%	1,649	1,622	930	289	368	657	674	653	566	304	383	323	345	141	51.00	69.00	40.00	107	110	68.00	6.00
Cashflow From Investing	-100.6%	-36.00	6,386	-26,891	4,449	3,886	2,754	1,866	-65.00	1,841	-24,184	-90.00	-24.00	-104	-49.00	-31.00	-3.00	-69.00	-94.00	-119	-105	-
Cashflow From Financing	-	-	-	-	-	-	-103	-	-	-	-35.00	1.00	35,068	4,068	90.00	12,234	3.00	4.00	4,285	2,030	16.00	19.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NSPR Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
REVENUES	$ 6,205	$ 5,171
COST OF REVENUES	4,398	4,054
GROSS PROFIT	1,807	1,117
OPERATING EXPENSES:
Research and development	7,981	7,810
Selling and marketing	3,865	3,664
General and administrative	11,104	8,356
Total operating expenses	22,950	19,830
LOSS FROM OPERATIONS	(21,143)	(18,713)
FINANCIAL INCOME , net:	1,292	250
LOSS BEFORE TAX EXPENSES	(19,851)	(18,463)
TAX EXPENSES	65	28
NET LOSS	$ (19,916)	$ (18,491)
NET LOSS PER SHARE - basic	$ (0.82)	$ (2.35)
NET LOSS PER SHARE - diluted	$ (0.82)	$ (2.35)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - basic	24,268,181	7,871,814
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING NET LOSS PER SHARE - diluted	24,268,181	7,871,814

NSPR Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)
$ in Thousands

Dec. 31, 2023

Dec. 31, 2022

CURRENT ASSETS:

Cash and cash equivalents

$ 9,640

$ 4,632

Short-term bank deposits

13,171

Marketable securities

29,383

Accounts receivable:

Trade, net

1,804

1,034

Other

648

213

Prepaid expenses

578

655

Inventory

2,106

1,621

TOTAL CURRENT ASSETS

44,159

21,326

NON-CURRENT ASSETS:

Property, plant and equipment, net

1,060

917

Operating lease right of use assets

1,473

1,554

Fund in respect of employee rights upon retirement

951

856

TOTAL NON-CURRENT ASSETS

3,484

3,327

TOTAL ASSETS

47,643

24,653

Accounts payable and accruals:

Trade

939

659

Other

5,081

4,411

TOTAL CURRENT LIABILITIES

6,020

5,070

LONG-TERM LIABILITIES:

Operating lease liabilities

1,038

1,195

Liability for employee rights upon retirement

1,084

995

TOTAL LONG-TERM LIABILITIES

2,122

2,190

TOTAL LIABILITIES

8,142

7,260

EQUITY:

Common stock, par value $0.0001 per share; 150,000,000 shares authorized at December 31, 2023 and 2022; 21,841,215 and 8,330,918 shares issued and outstanding at December 31, 2023 and 2022, respectively

Preferred C shares, par value $0.0001 per share; 1,172,000 shares authorized at December 31, 2023 and 2022; 1,718 shares issued and outstanding at December 31, 2023 and 2022;

^[1]

Additional paid-in capital

261,000

218,977

Accumulated deficit

(221,501)

(201,585)

Total equity

39,501

17,393

Total liabilities and equity

$ 47,643

$ 24,653

[1]	Represents an amount less than $1

About InspireMD Inc

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Delivery System, a mesh-covered self-expanding carotid stent; SwitchGuard, a non-invasive transcarotid artery revascularization device; and NGuard EPS for treating acute stroke with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

CEO	Mr. Marvin L. Slosman
WEBSITE	inspiremd.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	55

InspireMD Inc Frequently Asked Questions

What is the ticker symbol for InspireMD Inc? What does NSPR stand for in stocks?

NSPR is the stock ticker symbol of InspireMD Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of InspireMD Inc (NSPR)?

As of Tue Apr 30 2024, market cap of InspireMD Inc is 45.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NSPR stock?

You can check NSPR's fair value in chart for subscribers.

What is the fair value of NSPR stock?

You can check NSPR's fair value in chart for subscribers. The fair value of InspireMD Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of InspireMD Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NSPR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is InspireMD Inc a good stock to buy?

The fair value guage provides a quick view whether NSPR is over valued or under valued. Whether InspireMD Inc is cheap or expensive depends on the assumptions which impact InspireMD Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NSPR.

What is InspireMD Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, NSPR's PE ratio (Price to Earnings) is -2.28 and Price to Sales (PS) ratio is 7.33. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NSPR PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on InspireMD Inc's stock?

In the past 10 years, InspireMD Inc has provided -0.831 (multiply by 100 for percentage) rate of return.